Biotech Stock Mailbag: Ranking Cheap Biotechs
According to ClinicalTrials.gov, the study is expected to have overall survival data available in September 2013.
@LTbioinvestor tweets, "How about $PTN? Can it get a place in your high-risk high return biotechs?"
No. Palatin Technologies (PTN) is cheap but too risky. Intranasal bremelanotide for erectile dysfunction blew up because the drug caused high blood pressure. Now, Palatin is testing an injectable version of bremelanotide for men with ED and women with female sexual dysfunction. The company says the new version of the drug is safer, but an injectable ED drug? That seems like a commercial flop in the making.
Traders and technicians may see something promising in the Palatin chart, but I see a company that was forced into a 1-for-10 reverse stock split in September 2010. The stock is down another 21% since the reverse split. That's not a comforting sign.Richard H. emails, "Why didn't you include Sangamo Biosciences (SGMO - Get Report) in your list? To me their pipeline is farther advanced then those listed and it is also already seeing some revenue from Dow and Sigma-Aldrich." Sangamo was considered but didn't make the "cheap" cut owing to a market value north of $300 million.
>To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: firstname.lastname@example.org.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts